Literature DB >> 9242998

Treatment of experimentally induced pneumonic pasteurellosis of young calves with tilmicosin.

D W Morck1, J K Merrill, M S Gard, M E Olson, P N Nation.   

Abstract

Twenty four (24) healthy male Holstein calves (< 70 kg) were each experimentally infected by intrabronchial inoculation of 4.0 x 10(9) viable cells of Pasteurella haemolytica-AI (B122) at Time = 0 h. At 1 h following inoculation animals received either: 1) Sham treatment with sterile 0.85% saline SC (n = 12); or 2) a single injection of 10 mg tilmicosin per kg body weight (n = 12). Calves that were non-infected and tilmicosin-treated were also included for determining tilmicosin concentrations in serum and lung tissue at 1, 2, 4, 6, 8, 24, 48, and 72 h (n = 3-per time). In the infected calves, response to therapy was monitored clinically. Serum samples were collected for determination of tilmicosin concentrations using HPLC. Any animal becoming seriously ill was humanely killed. Complete necropsy examinations were performed on all animals and included gross pathologic changes, bacteriologic analysis, histopathology, and determination of pulmonary concentrations of tilmicosin. Tilmicosin treated animals responded significantly better to therapy than saline-treated control calves. Clinical assessment of calves during the study indicated that tilmicosin-treated calves had significantly improved by T = 8 h compared to satine-treated animals (P < 0.05). At necropsy tilmicosin-treated calves had significantly less severe gross and histological lesions (P < 0.05) of the pulmonary tissue. Of the 12 saline-treated calves, 92% (11/12) had Pasteurella haemolytica-A1 in lung tissue, while of the tilmicosin-treated calves 0% (0/12) cultured positive for P. haemolytica. Mean (+/- standard error) serum tilmicosin concentrations in infected calves peaked at 1 h post-injection (1.10 +/- 0.06 micrograms/mL) and rapidly decreased to 0.20 +/- 0.03 microgram/mL, well below the MIC of 0.50 microgram/mL for P. haemolytica-A1 (B122), by 12 h. These serum concentrations were very similar to serum concentrations of tilmicosin in non-infected tilmicosin-treated calves. Lung tissue concentrations of the antibiotic were comparatively high, even at 72 h post-infection (6.50 +/- 0.75 ppm). Lung tissue concentrations at 72 h were significantly higher in experimentally infected calves than in non-infected tilmicosin-treated animals (P < 0.05). These data demonstrate that tilmicosin was effective in treating experimentally-induced pneumonic pasteurellosis as determined by alleviation of clinical signs, pathological findings at post mortem, and presence of viable bacteria from the lung. Concentrations substantially above MIC for P. haemolytica were present in lung tissue even at 72 h following a single subcutaneous injection of 10 mg tilmicosin per kg body weight.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242998      PMCID: PMC1189402     

Source DB:  PubMed          Journal:  Can J Vet Res        ISSN: 0830-9000            Impact factor:   1.310


  8 in total

1.  Tilmicosin as a single injection treatment for respiratory disease of feedlot cattle.

Authors:  P E Gorham; L H Carroll; J W McAskill; L E Watkins; E E Ose; L V Tonkinson; J K Merrill
Journal:  Can Vet J       Date:  1990-12       Impact factor: 1.008

2.  Efficacy of tilmicosin in treatment of pulmonary infections in calves.

Authors:  T Picavet; E Muylle; L A Devriese; J Geryl
Journal:  Vet Rec       Date:  1991-11-02       Impact factor: 2.695

3.  A perspective on respiratory disease in feedlot cattle.

Authors:  R G Thomson
Journal:  Can Vet J       Date:  1980-06       Impact factor: 1.008

4.  Long-acting antibiotic formulations in the treatment of calf pneumonia: a comparative study of tilmicosin and oxytetracycline.

Authors:  R Laven; A H Andrews
Journal:  Vet Rec       Date:  1991-08-10       Impact factor: 2.695

5.  Use of tilmicosin for treatment of pasteurellosis in rabbits.

Authors:  S G McKay; D W Morck; J K Merrill; M E Olson; S C Chan; K M Pap
Journal:  Am J Vet Res       Date:  1996-08       Impact factor: 1.156

6.  Effect of a new macrolide antibiotic (tilmicosin) on pneumonia experimentally induced in calves by Mycoplasma bovis and Pasteurella haemolytica.

Authors:  R N Gourlay; L H Thomas; S G Wyld; C J Smith
Journal:  Res Vet Sci       Date:  1989-07       Impact factor: 2.534

7.  Prophylactic efficacy of tilmicosin for bovine respiratory tract disease.

Authors:  D W Morck; J K Merrill; B E Thorlakson; M E Olson; L V Tonkinson; J W Costerton
Journal:  J Am Vet Med Assoc       Date:  1993-01-15       Impact factor: 1.936

8.  Structure-activity studies of 20-deoxo-20-amino derivatives of tylosin-related macrolides.

Authors:  H A Kirst; K E Willard; M Debono; J E Toth; B A Truedell; J P Leeds; J L Ott; A M Felty-Duckworth; F T Counter; E E Ose
Journal:  J Antibiot (Tokyo)       Date:  1989-11       Impact factor: 2.649

  8 in total
  7 in total

1.  Adverse outcome of using tilmicosin in a lamb with multiple ventricular septal defects.

Authors:  Georgios Christodoulopoulos
Journal:  Can Vet J       Date:  2009-01       Impact factor: 1.008

Review 2.  Immuno-modulation and anti-inflammatory benefits of antibiotics: the example of tilmicosin.

Authors:  André G Buret
Journal:  Can J Vet Res       Date:  2010-01       Impact factor: 1.310

3.  Tilmicosin induces apoptosis in bovine peripheral neutrophils in the presence or in the absence of Pasteurella haemolytica and promotes neutrophil phagocytosis by macrophages.

Authors:  A C Chin; W D Lee; K A Murrin; D W Morck; J K Merrill; P Dick; A G Buret
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Tilmicosin does not inhibit interleukin-8 gene expression in the bovine lung experimentally infected with Mannheimia (Pasteurella) haemolytica.

Authors:  S Goubau; D W Morck; A Buret
Journal:  Can J Vet Res       Date:  2000-10       Impact factor: 1.310

5.  Anti-Inflammatory benefits of antibiotic-induced neutrophil apoptosis: tulathromycin induces caspase-3-dependent neutrophil programmed cell death and inhibits NF-kappaB signaling and CXCL8 transcription.

Authors:  Carrie D Fischer; Jennifer K Beatty; Cheryl G Zvaigzne; Douglas W Morck; Merlyn J Lucas; A G Buret
Journal:  Antimicrob Agents Chemother       Date:  2010-10-18       Impact factor: 5.191

6.  In vitro susceptibilities of Leptospira spp. and Borrelia burgdorferi isolates to amoxicillin, tilmicosin, and enrofloxacin.

Authors:  Doo Kim; Dorsey Kordick; Thomas Divers; Yung Fu Chang
Journal:  J Vet Sci       Date:  2006-12       Impact factor: 1.672

7.  Milk and blood pharmacokinetics of tylosin and tilmicosin following parenteral administrations to cows.

Authors:  Tulay Avci; Muammer Elmas
Journal:  ScientificWorldJournal       Date:  2014-08-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.